Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Funding To Give ViroMed ‘Favorable Position’ For Gene Therapy Deal

Executive Summary

ViroMed joins a group of South Korean bioventures launching share offerings to fund R&D activities, in its case to beef up the clinical data package for its lead project VM202, which should in turn help with a licensing out deal for the gene therapy.

Advertisement

Related Content

A Peek Into Korean Bioventures’ Success Factors, Challenges
Genexine Raises New Funds To Progress Promising HPV, Other Projects
Orphan Drugs Korean Pharmas’ Ticket To Global Success?
Kolon Ramps Up For Novel Osteoarthritis Cell Therapy

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

SC096969

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel